Olanzapine Market Report 2026

Olanzapine Market Overview

• Olanzapine market size has reached to $2.63 billion in 2025 • Expected to grow to $3.11 billion in 2030 at a compound annual growth rate (CAGR) of 3.6% • Growth Driver: Olanzapine Market Surges Amidst Escalating Emotional Illness And Mental Health Challenges • Market Trend: Teva Pharmaceutical And Royalty Pharma Partner For Olanzapine's Clinical Advancements • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Olanzapine Market?

Olanzapine is an atypical antipsychotic medication that is used to treat various mental disorders such as schizophrenia, bipolar disorder, and depression associated with bipolar disorder. It works by modulating the effects of certain chemicals in the brain, particularly dopamine and serotonin. The main types of olanzapine include therapies such as monotherapy and combination therapy. Monotherapy is a type of medical treatment in which a single medication, such as olanzapine, or therapy is used to treat a particular condition or disease, including schizophrenia, bipolar disorder, and major depressive disorder. Monotherapy with olanzapine involves the use of this medication alone without combining it with other medications. These are administered by oral and parenteral routes to treat schizophrenia, bipolar disorder, and other conditions by hospitals, home care, specialty clinics, and others.

What Is The Olanzapine Market Growth Forecast?

The olanzapine market size is expected to see steady growth in the next few years. It will grow to $3.11 billion in 2030 at a compound annual growth rate (CAGR) of 3.6%. The growth in the forecast period can be attributed to growth in global mental health awareness, rising adoption of combination drug therapies, expanding access to psychiatric care in emerging economies, development of improved olanzapine formulations, increasing focus on treatment adherence. Major trends in the forecast period include rising use of long-acting injectable olanzapine, growing preference for orally disintegrating tablets, expansion of combination therapies in bipolar disorder, increasing generic penetration in emerging markets, shift toward home-based mental health management.

Global Olanzapine Market Segmentation

1) By Therapy Type: Monotherapy, Combinational Therapy 2) By Route Of Administration: Oral, Parenteral 3) By Application: Schizophrenia, Bipolar Disorder, Other Applications 4) By End-Users: Hospitals, Homecare, Specialty Clinics, Other End-Users Subsegments: 1) By Monotherapy: Tablet Formulation, Orally Disintegrating Tablets, Injectable Formulation 2) By Combinational Therapy: Olanzapine + Fluoxetine, Olanzapine + Other Antipsychotics, Olanzapine + Mood Stabilizers, Olanzapine + Antidepressants

What Is The Driver Of The Olanzapine Market?

The increasing prevalence of emotional illness and mental troubles is expected to propel the growth of the olanzapine market. Emotional illness and mental trouble refer to conditions or disorders that affect an individual's mental and emotional well-being. The increased emotional illness and mental health issues are driving the demand for mental health treatment solutions, including olanzapine, which is an atypical antipsychotic that is primarily utilized to treat conditions such as schizophrenia and bipolar disorder and may also be prescribed in conjunction with other medications for the treatment of depression. For instance, in May 2024, according to the American Psychiatric Association, a US-based professional organization, a rising share of adults reported increased anxiety, climbing from 32% in 2022 to 37% in 2023 and reaching 43% in 2024. Therefore, the increasing prevalence of emotional illness and mental troubles is driving the growth of the olanzapine industry.

Key Players In The Global Olanzapine Market

Major companies operating in the olanzapine market are Aurobindo Pharma Ltd., Teva Pharmaceutical Industries Limited, Dr. Reddy's Laboratories Ltd., Sun Pharmaceutical Industries Limited, Torrent Group, Apotex Inc., Mylan N.V., Viatris Inc., Zydus Cadila Healthcare Ltd., Endo International plc, Lupin Limited, Cipla Inc., Eli Lilly and Company, Zhejiang Langhua Pharmaceutical Co. Ltd., Jiangsu Hansoh Pharmaceutical Group Co. Ltd., Sandoz International GmbH, Changzhou Huasheng Pharmaceutical Co. Ltd., Par Pharmaceutical, Jubilant Pharmova Limited, Hansoh Pharmaceutical, Egis Pharmaceuticals plc, Actavis Group hf., Hexal AG

Global Olanzapine Market Trends and Insights

Major companies operating in the olanzapine market are adopting a strategic partnership approach to bring the olanzapine drug to market as the first long-acting drug with a favorable safety profile. Strategic partnerships refer to a process in which companies leverage each other's strengths and resources to achieve mutual benefits and success. For instance, in November 2023, Teva Pharmaceutical Industries Ltd., an Israel-based pharmaceutical company, partnered with Royalty Pharma PLC, a US-based biopharmaceutical company. With this partnership, they aim to further accelerate the clinical research program for Teva's olanzapine LAI (TEV-‘749), a once-monthly subcutaneous long-acting injection of the atypical antipsychotic olanzapine that is currently in Phase 3 for the treatment of schizophrenia.

What Are Latest Mergers And Acquisitions In The Olanzapine Market?

In April 2023, Cheplapharm Arzneimittel GmbH, a Germany-based pharmaceutical company engaged in branded drugs, medical products, supplements, and cosmetics, acquired worldwide commercial rights for Zyprexa from Eli Lilly and Company for an undisclosed amount. Through this acquisition Cheplapharm strengthened its portfolio in the therapeutic area of the central nervous system. Eli Lilly and Company is a US-based pharmaceutical company engaged in olanzapine medications.

Regional Insights

North America was the largest region in the olanzapine market in 2025.Asia-Pacific is expected to be the fastest-growing region in the global olanzapine market report during the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Olanzapine Market?

The olanzapine market consists of sales of branded and generic olanzapine medications. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Olanzapine Market Report 2026?

The olanzapine market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the olanzapine industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.